Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.
A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Kitchener, Ontario, Canada
- Pfizer Investigational Site
-
Sarnia, Ontario, Canada
- Pfizer Investigational Site
-
Toronto, Ontario, Canada
- Pfizer Investigational Site
-
-
Quebec
-
St. Leonard, Quebec, Canada
- Pfizer Investigational Site
-
Trois-Rivieres, Quebec, Canada
- Pfizer Investigational Site
-
-
-
-
-
LYON Cedex 03, France
- Pfizer Investigational Site
-
Lille, France
- Pfizer Investigational Site
-
Montpellier, France
- Pfizer Investigational Site
-
PARIS cedex 18, France
- Pfizer Investigational Site
-
-
-
-
-
Patras, Greece
- Pfizer Investigational Site
-
Thessaloniki, Greece
- Pfizer Investigational Site
-
-
Athens
-
Goudi, Athens, Greece
- Pfizer Investigational Site
-
-
-
-
-
Beer Sheba, Israel
- Pfizer Investigational Site
-
Haifa, Israel
- Pfizer Investigational Site
-
Petach Tikva, Israel
- Pfizer Investigational Site
-
Tel- Aviv, Israel
- Pfizer Investigational Site
-
-
-
-
-
Bologna, Italy
- Pfizer Investigational Site
-
Firenze, Italy
- Pfizer Investigational Site
-
L'Aquila, Italy
- Pfizer Investigational Site
-
Milano, Italy
- Pfizer Investigational Site
-
Roma, Italy
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Russian Federation
- Pfizer Investigational Site
-
-
-
-
-
Alicante, Spain
- Pfizer Investigational Site
-
Barcelona, Spain
- Pfizer Investigational Site
-
Madrid, Spain
- Pfizer Investigational Site
-
Malaga, Spain
- Pfizer Investigational Site
-
Sevilla, Spain
- Pfizer Investigational Site
-
Valencia, Spain
- Pfizer Investigational Site
-
-
Santa Cruz De Tenerife
-
La Laguna, Santa Cruz De Tenerife, Spain
- Pfizer Investigational Site
-
-
-
-
-
Bath, United Kingdom
- Pfizer Investigational Site
-
Coventry, United Kingdom
- Pfizer Investigational Site
-
Doncaster, United Kingdom
- Pfizer Investigational Site
-
Dundee, United Kingdom
- Pfizer Investigational Site
-
Glasgow, United Kingdom
- Pfizer Investigational Site
-
-
Durham
-
Belmont, Durham, United Kingdom
- Pfizer Investigational Site
-
-
Middlesex
-
Ashford, Middlesex, United Kingdom
- Pfizer Investigational Site
-
-
Surrey
-
Weybridge, Surrey, United Kingdom
- Pfizer Investigational Site
-
-
Wilts.
-
Chippenham, Wilts., United Kingdom
- Pfizer Investigational Site
-
-
Wiltshire
-
Trowbridge, Wiltshire, United Kingdom
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented clinical diagnosis of ED by using IIEF-EF domain with score of ≤ 25.
- Subjects must be in a stable relationship with the same partner for at least 6 months and willing to attempt sexual intercourse.
Exclusion Criteria:
- Subjects in whom sexual activity is inadvisable in the opinion of the investigator such as significant cardiovascular disease in the last 6 months; including cardiac failure, myocardial infarction, unstable angina, stroke or transient ischemic attack (TIA), symptomatic or clinically significant cardiac arrhythmias including atrial fibrillation.
- Subjects who are currently taking or are likely to be treated with nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or as aerosols) on either regular or intermittent basis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Change in IIEF erectile function domain score at the end of double blind treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Change in other IIEF domain scores; Response to other questionnaires regarding treatment satisfaction, safety and tolerability.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A1481237
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.